

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

B6

#5

PCT09

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001
 TIME: 11:51:13

Input Set : A:\Nih386-2.app
 Output Set: N:\CRF3\10292001\I869003.raw

3 <110> APPLICANT: Scala, Giuseppe
 4 Chen, Xueni
 5 Cohen, Oren J.
 6 Fauci, Anthony
 7 The Government of the United States of America
 8 as represented by the Secretary of the
 9 Department of Health and Human Services
 11 <120> TITLE OF INVENTION: Novel HIV Related Peptides
 13 <130> FILE REFERENCE: 015280-386200US
 15 <140> CURRENT APPLICATION NUMBER: US 09/869,003 ✓
 16 <141> CURRENT FILING DATE: 2001-06-22
 18 <150> PRIOR APPLICATION NUMBER: US 60/115,430
 19 <151> PRIOR FILING DATE: 1999-01-11
 21 <150> PRIOR APPLICATION NUMBER: US 60/132,760
 22 <151> PRIOR FILING DATE: 1999-05-06
 24 <150> PRIOR APPLICATION NUMBER: WO PCT/US00/00372
 25 <151> PRIOR FILING DATE: 2000-01-07
 27 <160> NUMBER OF SEQ ID NOS: 34
 29 <170> SOFTWARE: PatentIn Ver. 2.1
 31 <210> SEQ ID NO: 1
 32 <211> LENGTH: 11
 33 <212> TYPE: PRT
 34 <213> ORGANISM: Artificial Sequence ✓
 36 <220> FEATURE:
 37 <223> OTHER INFORMATION: Description of Artificial Sequence: antigenic ✓
 38 determinant peptide
 40 <220> FEATURE:
 41 <221> NAME/KEY: MOD_RES
 42 <222> LOCATION: (1)
 43 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 44 acid naturally flanking the subsequence at positions ✓
 45 2-10 in HIV-1
 47 <220> FEATURE:
 48 <221> NAME/KEY: MOD_RES
 49 <222> LOCATION: (11)
 50 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 51 acid naturally flanking the subsequence at positions ✓
 52 2-10 in HIV-1
 54 <400> SEQUENCE: 1
 W--> 55 Xaa Lys Ser Ser Gly Lys Leu Ile Ser Leu Xaa
 56 1 5 10 ✓
 59 <210> SEQ ID NO: 2
 60 <211> LENGTH: 11
 61 <212> TYPE: PRT
 62 <213> ORGANISM: Artificial Sequence ✓
 64 <220> FEATURE:
 65 <223> OTHER INFORMATION: Description of Artificial Sequence: antigenic ✓

ENTERED

P.5

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001

TIME: 11:51:13

Input Set : A:\Nih386-2.app

Output Set: N:\CRF3\10292001\I869003.raw

66 determinant peptide
 68 <220> FEATURE:
 69 <221> NAME/KEY: MOD_RES
 70 <222> LOCATION: (1)
 71 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 72 acid naturally flanking the subsequence at positions 2-10 in HIV-1
 73
 75 <220> FEATURE:
 76 <221> NAME/KEY: MOD_RES
 77 <222> LOCATION: (11)
 78 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 79 acid naturally flanking the subsequence at positions 2-10 in HIV-1
 80
 82 <400> SEQUENCE: 2
 W--> 83 Xaa Cys Asn Gly Arg Leu Tyr Cys Gly Pro Xaa
 84 1 5 10
 87 <210> SEQ ID NO: 3
 88 <211> LENGTH: 11
 89 <212> TYPE: PRT
 90 <213> ORGANISM: Artificial Sequence
 92 <220> FEATURE:
 93 <223> OTHER INFORMATION: Description of Artificial Sequence: antigenic
 94 determinant peptide
 96 <220> FEATURE:
 97 <221> NAME/KEY: MOD_RES
 98 <222> LOCATION: (1)
 99 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 100 acid naturally flanking the subsequence at positions 2-10 in HIV-1
 101
 103 <220> FEATURE:
 104 <221> NAME/KEY: MOD_RES
 105 <222> LOCATION: (11)
 106 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
 107 acid naturally flanking the subsequence at positions 2-10 in HIV-1
 108
 110 <400> SEQUENCE: 3
 W--> 111 Xaa Gly Thr Lys Leu Val Cys Phe Ala Ala Xaa
 112 1 5 10
 115 <210> SEQ ID NO: 4
 116 <211> LENGTH: 9
 117 <212> TYPE: PRT
 118 <213> ORGANISM: Artificial Sequence
 120 <220> FEATURE:
 121 <223> OTHER INFORMATION: Description of Artificial Sequence: p195 epitope
 122 antigenic determinant peptide
 124 <400> SEQUENCE: 4
 125 Lys Ser Ser Gly Lys Leu Ile Ser Leu
 126 1 5
 129 <210> SEQ ID NO: 5

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001
TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

130 <211> LENGTH: 9
131 <212> TYPE: PRT
132 <213> ORGANISM: Artificial Sequence ✓
134 <220> FEATURE:
135 <223> OTHER INFORMATION: Description of Artificial Sequence:p217 epitope ✓
136 antigenic determinant peptide
138 <400> SEQUENCE: 5
139 Cys Asn Gly Arg Leu Tyr Cys Gly Pro
140 1 5
143 <210> SEQ ID NO: 6
144 <211> LENGTH: 9
145 <212> TYPE: PRT
146 <213> ORGANISM: Artificial Sequence ✓
148 <220> FEATURE:
149 <223> OTHER INFORMATION: Description of Artificial Sequence:p197 epitope ✓
150 antigenic determinant peptide
152 <400> SEQUENCE: 6
153 Gly Thr Lys Leu Val Cys Phe Ala Ala
154 1 5
157 <210> SEQ ID NO: 7
158 <211> LENGTH: 9
159 <212> TYPE: PRT
160 <213> ORGANISM: Artificial Sequence ✓
162 <220> FEATURE:
163 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic ✓
164 determinant peptide
166 <400> SEQUENCE: 7
167 Glu Ala Thr Val Val Tyr Pro Ala Pro
168 1 5
171 <210> SEQ ID NO: 8
172 <211> LENGTH: 9
173 <212> TYPE: PRT
174 <213> ORGANISM: Artificial Sequence ✓
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Description of Artificial Sequence:p54 epitope ✓
178 with no obvious sequence homology with HIV protein
179 domains
181 <400> SEQUENCE: 8
182 Thr Lys Thr Leu Ile Tyr Gly Gly Ala
183 1 5
186 <210> SEQ ID NO: 9
187 <211> LENGTH: 9
188 <212> TYPE: PRT
189 <213> ORGANISM: Artificial Sequence ✓
191 <220> FEATURE:
192 <223> OTHER INFORMATION: Description of Artificial Sequence:p163 epitope ✓
193 with no obvious sequence homology with HIV protein ✓
194 domains
196 <400> SEQUENCE: 9

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001
TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

197 Lys Arg Ile Val Ile Gly Pro Gln Thr
198 1 5
201 <210> SEQ ID NO: 10
202 <211> LENGTH: 9
203 <212> TYPE: PRT
204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
208 determinant peptide
210 <400> SEQUENCE: 10
211 Cys Cys Gly Cys Leu Thr Cys Ser Val
212 1 5
215 <210> SEQ ID NO: 11
216 <211> LENGTH: 10
217 <212> TYPE: PRT
218 <213> ORGANISM: Artificial Sequence
220 <220> FEATURE:
221 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
222 determinant peptide
224 <400> SEQUENCE: 11
225 Ser Gly Arg Leu Tyr Cys His Glu Ser Trp
226 1 5 10
229 <210> SEQ ID NO: 12
230 <211> LENGTH: 9
231 <212> TYPE: PRT
232 <213> ORGANISM: Artificial Sequence
234 <220> FEATURE:
235 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
236 determinant peptide
238 <400> SEQUENCE: 12
239 Phe Ala Leu Ser His Tyr Asp Lys Pro
240 1 5
243 <210> SEQ ID NO: 13
244 <211> LENGTH: 9
245 <212> TYPE: PRT
246 <213> ORGANISM: Artificial Sequence
248 <220> FEATURE:
249 <223> OTHER INFORMATION: Description of Artificial Sequence:p689 epitope
250 with no obvious sequence homology with HIV protein
251 domains
253 <400> SEQUENCE: 13
254 Arg Pro Thr Leu Arg Phe Gln Gly Ala
255 1 5
258 <210> SEQ ID NO: 14
259 <211> LENGTH: 20
260 <212> TYPE: PRT
261 <213> ORGANISM: Artificial Sequence
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Description of Artificial Sequence:p195 analog

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001
TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

265 antigenic determinant peptide
 267 <400> SEQUENCE: 14
 268 Glu Gly Glu Phe Cys Lys Ser Ser Gly Lys Leu Ile Ser Leu Cys Gly
 269 1 5 10 15
 271 Asp Pro Ala Lys
 272 20
 275 <210> SEQ ID NO: 15
 276 <211> LENGTH: 20
 277 <212> TYPE: PRT
 278 <213> ORGANISM: Artificial Sequence ✓
 280 <220> FEATURE:
 281 <223> OTHER INFORMATION: Description of Artificial Sequence:p197 analog
 282 antigenic determinant peptide
 284 <400> SEQUENCE: 15
 285 Glu Gly Glu Phe Cys Gln Thr Lys Leu Val Cys Phe Ala Ala Ala Gly
 286 1 5 10 15
 288 Asp Pro Ala Lys
 289 20
 292 <210> SEQ ID NO: 16
 293 <211> LENGTH: 20
 294 <212> TYPE: PRT
 295 <213> ORGANISM: Artificial Sequence ✓
 297 <220> FEATURE:
 298 <223> OTHER INFORMATION: Description of Artificial Sequence:p217 analog
 299 antigenic determinant peptide
 301 <400> SEQUENCE: 16
 302 Glu Gly Glu Phe Cys Cys Asn Gly Arg Leu Tyr Cys Gln Pro Cys Gly
 303 1 5 10 15
 305 Asp Pro Ala Lys
 306 20
 309 <210> SEQ ID NO: 17
 310 <211> LENGTH: 20
 311 <212> TYPE: PRT ✓
 312 <213> ORGANISM: Artificial Sequence
 314 <220> FEATURE:
 315 <223> OTHER INFORMATION: Description of Artificial Sequence:p287 analog
 316 antigenic determinant peptide
 318 <400> SEQUENCE: 17
 319 Glu Gly Glu Phe Cys Cys Ala Gly Gln Leu Thr Cys Ser Val Cys Gly
 320 1 5 10 15
 322 Asp Pro Ala Lys
 323 20
 326 <210> SEQ ID NO: 18
 327 <211> LENGTH: 12
 328 <212> TYPE: PRT ✓
 329 <213> ORGANISM: Artificial Sequence
 331 <220> FEATURE:
 332 <223> OTHER INFORMATION: Description of Artificial Sequence:p335 analog
 333 antigenic determinant peptide ✓

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/869,003

DATE: 10/29/2001
TIME: 11:51:14

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

L:55 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:539 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:542 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:548 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:551 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:554 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:557 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:585 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:588 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:594 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:597 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:600 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:603 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:631 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:634 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:637 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:640 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:643 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:646 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33